Dr. Therese Canaris discusses CurieDx's clinical and regulatory roadmap on The Pitch.
Assertion Not checkable as stated
CurieDx's strep diagnostic is 88% accurate, beating physician visual evaluations
“The rapid swab that you traditionally do at the doctor's office, the one that comes back in 15 minutes, that's about 95% accurate, so it's good, but it's not perfect, and, ah, the, you know, physicians are 64%, so we are around 88% right now accuracy”
Assertion Not checkable as stated
Canaris: CurieDx Proof-of-Concept UTI Model Achieves 88% Accuracy
“And we have, just on the proof of concept model, we have 88% accuracy on that.”
Prediction Not checkable as stated
Canaris: CurieDx will reach $6M total revenue by late 2026
“Six million total by the end of 26.”
Disclosure
CurieDX is raising $4M to reach 10,000 patients and secure FDA clearance
“We're now raising four million, which helps us reach our first 10,000 patients and get the strep product through FDA from a screening tool to a diagnostic.”
Assertion Not checkable as stated
Advisors say enterprise health organizations evaluate strategic partnerships at 10,000 users
“We have advisors at Amazon One Medical and also Care First Blue Cross Blue Shield and feedback that they've given us is when we get into the 10,000 user range, that's when they start paying attention and looking at strategic partnerships.”
Disclosure
CurieDx will pivot from direct-to-consumer back to B2B in Q3 2025
“The intention is direct to consumer for the relatively short period, around six months from now, so like Q three of 25, we start pouring efforts back into the B to B component and slowly build up that urgent care and small to medium practice customer base.”